We are international
Donate
TEXT SIZE   


ASCO 2012: Dr. Lonial - Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM).
Sagar Lonial, MD
Emory University School of Medicine
Atlanta, Georgia, USA
06.26.12


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles